Milestone Pharmaceuticals downgraded to Hold from Buy at TD Cowen
TD Cowen downgraded Milestone Pharmaceuticals (MIST) to Hold from Buy and suspended the firm’s price target after Milestone ...
MPR2d
FDA Decision on Etripamil Nasal Spray Delayed Due to Nonclinical Issues
The Food and Drug Administration (FDA) has issued a Complete Response Letter to Milestone Pharmaceuticals regarding the New Drug Application (NDA) for ...
Healio3d
Lifestyle changes plus drug therapy inferior to catheter ablation in AF, obesity
For patients with atrial fibrillation and obesity, lifestyle modification plus antiarrhythmic drug therapy conferred various ...
Milestone Pharmaceuticals Shares Hit New Low After FDA Rejects Etripamil
Milestone in 2023 agreed to sell a royalty interest in etripamil to RTW Investments for $75 million, subject to the company receiving FDA approval of the drug by the end of September 2025. Write to ...